LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

3.49 -1.97

Buy Sell

Overview

Share price change

24h

Current

Min

3.45

Max

3.5

Key metrics
By Trading Economics
Income	9.6M -162M
Sales	-14M 5.2M
Profit margin	-3,135.324
Employees	800
EBITDA	6.4M -141M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+122.06% upside

Dividends
By Dow Jones
Next Earnings	27 lut 2026

Market Stats
By TradingEconomics
Market Cap	-300M 2.1B
Previous open	5.46
Previous close	3.49

News Sentiment

By Acuity

50%

127 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 lut 2026, 23:21 UTC

Acquisitions, Mergers, Takeovers

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 lut 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 lut 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 lut 2026, 23:06 UTC

Earnings

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Shareholders to Receive A$5.20/Share in Cash

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 lut 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 lut 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 lut 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 lut 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 lut 2026, 20:48 UTC

Earnings

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 lut 2026, 20:47 UTC

Earnings

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 lut 2026, 20:46 UTC

Earnings

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 lut 2026, 20:45 UTC

Earnings

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 lut 2026, 20:43 UTC

Earnings

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 lut 2026, 20:42 UTC

Earnings

BlueScope Net Debt A$2.2 Million at Dec. 31

15 lut 2026, 20:42 UTC

Earnings

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 lut 2026, 20:41 UTC

Earnings

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 lut 2026, 20:39 UTC

Earnings

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

122.06% upside

12 Months Forecast

Average 7.75 USD 122.06%

High 11 USD

Low 5 USD

Based on 4 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

127 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.